Sylvia Taylor, PhD, MPH, MBA

Medical Evidence, Vaccines and Immune Therapies Unit, AstraZeneca, Cambridge, UK, United Kingdom

Poster(s):

• (398) Increased Risk of Severe COVID-19 Outcomes Across all Groups of Individuals with Hematological Malignancies, Solid Tumors, and Solid Organ Transplants Compared with the General Population: Initial Results from INFORM, a Retrospective Health Database Observational Study in England
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET

• (470) Clinical Effectiveness of The Monoclonal Antibody Combination Tixagevimab-Cilgavimab (T/C) as Pre-Exposure Prophylaxis (PReP) of COVID-19 among Patients (pts) with Moderate to Severe Immunocompromised (IC) Conditions across a Large U.S. Healthcare System: A Propensity Score-Matched Retrospective Cohort Study
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET

• (471) In-Depth Characterization of SARS-CoV-2 Variants Causing Breakthrough COVID-19 Among Hospitalized Immunocompromised (IC) Patients with or without Prior Exposure to Tixagevimab-Cilgavimab (T/C) Pre-Exposure Prophylaxis (PrEP)
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET

• (2292) Measuring Effectiveness against a Shifting Variant Landscape: COVID-19 Example in the Department of Veterans Affairs
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET